drugset
drugset / Trial / NCT04349800

A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers

NCT04349800 ↗

Phase 1 Completed 84 enrolled KalVista Pharmaceuticals, Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A safety, tolerability, pharmacokinetic and food effect study of KVD900 in healthy volunteers.

Timeline

Start
2018-01-04
Primary completion
2018-09-10
Completion
2018-09-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sebetralstat Small molecule 5 mg Oral
Subject Sebetralstat Small molecule 10 mg Oral
Subject Sebetralstat Small molecule 20 mg Oral
Subject Sebetralstat Small molecule 40 mg Oral
Subject Sebetralstat Small molecule 80 mg Oral
Subject Sebetralstat Small molecule 160 mg Oral
Subject Sebetralstat Small molecule 300 mg Oral
Subject Sebetralstat Small molecule 600 mg Oral

Indications

hereditary angioedema